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Abstract
Genetic variation may mediate the increased risk of cardiovascular disease (CVD) in chemotherapy-treated testicular cancer
(TC) patients compared to the general population. Involved single nucleotide polymorphisms (SNPs) might differ from
known CVD-associated SNPs in the general population. We performed an explorative genome-wide association study
(GWAS) in TC patients. TC patients treated with platinum-based chemotherapy between 1977 and 2011, age ≤55 years at
diagnosis, and ≥3 years relapse-free follow-up were genotyped. Association between SNPs and CVD occurrence during
treatment or follow-up was analyzed. Data-driven Expression Prioritized Integration for Complex Trait (DEPICT) provided
insight into enriched gene sets, i.e., biological themes. During a median follow-up of 11 years (range 3–37), CVD occurred
in 53 (14%) of 375 genotyped patients. Based on 179 SNPs associated at p ≤ 0.001, 141 independent genomic loci associated
with CVD occurrence. Subsequent, DEPICT found ten biological themes, with the RAC2/RAC3 network (linked to
endothelial activation) as the most prominent theme. Biology of this network was illustrated in a TC cohort (n= 60) by
increased circulating endothelial cells during chemotherapy. In conclusion, the ten observed biological themes highlight
possible pathways involved in CVD in chemotherapy-treated TC patients. Insight in the genetic susceptibility to CVD in TC
patients can aid future intervention strategies.
Introduction
Testicular cancer (TC) is the most common malignancy in
men between 20 and 40 years of age. Over 80% of patients
with metastatic TC is cured with platinum-based che-
motherapy [1]. Consequently, the number of TC survivors
steadily increases. High cure rates come at the trade-off of
increased risk of cardiovascular disease (CVD), attributed to
chemotherapy. Compared to age-matched controls, patients
treated with bleomycin, etoposide, and cisplatin che-
motherapy have a hazard ratio for coronary artery disease of
5.7 (95% confidence interval, CI, 1.9–17.1), and for ather-
osclerotic disease of 4.7 (95% CI, 1.8–12.2) [2]. Moreover,
cardiovascular mortality is increased after chemotherapy for
TC with a standardized mortality ratio of 1.36 (95% CI,
1.03–1.78) [3]. In these relatively young men, the burden of
cardiovascular morbidity and mortality due to chemother-
apy is an important determinant of long-term outcome.
Genetic variation is thought to mediate in part the increased
risk of CVD in chemotherapy-treated TC patients. However,
involved single nucleotide polymorphisms (SNPs) might dif-
fer from the currently known SNPs associated with increased
risk of CVD in the general population.
A limited number of studies reported on associations
between SNPs and late complications of TC treatment.
These studies mostly focused on SNPs in specific genes
rather than using unbiased genome-wide approaches. SNPs
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in the glutathione S-transferase genes GSTP1 and GSTM3
have been associated with neurotoxicity and ototoxicity in
platinum-treated TC patients [4–6]. SNPs in the 5-α-
reductase type II (SRD5A2) gene were associated with
prevalence of the metabolic syndrome in TC survivors after
platinum-based chemotherapy [7]. This finding, however,
could not be replicated [8]. A recent study in 188 platinum-
treated TC patients reported that a SNP in solute carrier
gene SLC16A5 was associated with cisplatin-induced oto-
toxicity [9]. In the Platinum Study cohort of 511 TC sur-
vivors, a SNP in the Wolframin ER transmembrane
glycoprotein (WFS1) was associated with ototoxicity [10].
To date, however, genetic variation has not been inves-
tigated in relation to CVD after TC treatment. As with the
reported associations between SNPs and neurotoxicity,
ototoxicity, and the metabolic syndrome, insight in genetic
variation and biological pathways associated with cardio-
vascular toxicity may help to estimate the increased risk for
CVD and to guide preventive cardiovascular intervention
strategies in TC patients treated with platinum-based
chemotherapy. We performed an exploratory genome-
wide association study (GWAS) in TC patients treated
with platinum-based chemotherapy to gain insight into the
SNPs underlying susceptibility to CVD in this population.
Patients and methods
Patient selection and phenotype data
Patients were selected from the institutional data-biobank
on TC patients treated at the University Medical Center
Groningen between 1977 and 2011. Inclusion criteria
were (a) advanced seminoma or non-seminoma TC, Royal
Marsden Hospital stage II, III, or IV, (b) treated with
platinum-based chemotherapy, (c) age ≤55 years at diag-
nosis, (d) ≥3 years relapse-free follow-up after start of first-
line chemotherapy, or after second-line chemotherapy if
given for early relapse within 3 years after TC diagnosis, (e)
no chemotherapy or malignancy prior to TC, and (f) no
CVD prior to TC.
The phenotype endpoint of the GWAS was the occur-
rence of a cardiovascular event during treatment or follow-
up, defined as any (1) coronary disease (myocardial
infarction, acute coronary syndrome), (2) cerebrovascular
infarction or transient ischemic attack, (3) cardiomyopathy
or heart failure, (4) thromboembolic event (deep venous
thrombosis, pulmonary embolism, venous access port-
associated), (5) peripheral artery disease, or (6) other car-
diovascular events (e.g., intracerebral hemorrhage, cardiac
arrhythmia, or cardiac valve regurgitation or stenosis).
Follow-up data were available through several prospective
TC studies and medical records. Follow-up was censored in
case of late relapse (more than 3 years after chemotherapy),
except for teratoma treated by surgery alone. In addition,
follow-up was censored in case of second malignancy,
except for non-melanoma skin cancer. Study protocols were
approved by the medical ethical review committee of the
University Medical Center Groningen (ethical protocol code
2006/041), performed in accordance with the Declaration
of Helsinki and each participant gave written informed
consent.
Genotype data
Germline DNA was isolated from blood using a standard
phenol-chloroform method or using the NucleoSpin Blood
XL column (Macherey-Nagel, BIOKÉ, Leiden, The Neth-
erlands). SNP array was performed according to suppliers’
protocol using an Illumina HumanCytoSNP-12 v2.1
BeadChip (Illumina, San Diego, California, US) covering
298,563 SNPs. SNPs were called using Illumina Geno-
meStudio v2011.1 (Genotyping v1.9.4; Illumina Genome
Viewer v1.9.0) and then exported (PLINK Input Report
Plug-in v2.1.3 for GenomeStudio Software).
Genotyping quality analysis
Quality analysis was performed using PLINK 1.07, filtering
out (1) SNPs with a call rate <95%, (2) samples with a SNP
call rate <95%, (3) samples with mismatch between repor-
ted and predicted sex, (4) SNPs that have minor allele fre-
quency <5%, and (5) samples with significant deviation
from the Hardy–Weinberg equilibrium (p < 0.0001) [11].
Association analysis
Association between SNPs and the occurrence of CVD was
assessed in PLINK by chi-squared test using the max(T)
permutation procedure with 25,000 permutations. SNPs
were clumped into independently associated loci based on
linkage disequilibrium, using an empirical p ≤ 0.001 as a
threshold for association of index SNPs (PLINK para-
meters: --clump-p1 0.001 --clump-p2 0.01 --clump-r2 0.20
--clump-kb 500).
Annotation of associated SNPs: genes
The loci found in the association analysis were annotated
with genes known to be associated with these loci using the
following three methods. First, we determined the nearest
gene(s) for each SNP as reported in dbSNP build 150.
Second, based on a publicly available large-scale mapping
of cis and trans expression quantitative trait loci (eQTLs) in
blood we determined for each SNP if that SNP has been
reported to affect the expression of any gene [12]. Third, the
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SNPs found in the association analysis were used as input
for the Data-driven Expression Prioritized Integration for
Complex Trait (DEPICT) framework [13]. At the core of
DEPICT, genes are functionally characterized by their
membership probabilities across 14,461 gene sets. DEPICT
takes genes in loci associated with the input SNPs and uses
the shared gene set memberships of those genes to prioritize
genes that have similar predicted functions. Genes were
reported by HGNC gene symbol if possible (retrieved using
R/Bioconductor package biomaRt 2.32.1), or alternatively
by Ensemble identifiers.
Insight in associated SNPs: gene sets clustered into
‘biological themes’
Next, gene set enrichment analysis was performed to gain
insight in the biology underlying the associations between
SNPs and the occurrence of CVD. To this end, DEPICT
takes genes in loci associated with the input SNPs, and tests
which of its 14,461 gene sets are enriched in those genes, at
a threshold of nominal p < 0.001. Since DEPICT is based on
reconstituted gene sets of known molecular pathways from
various sources, overlap between the reconstituted gene sets
can be expected. Therefore, the enriched gene sets were
clustered into ‘biological themes’ using affinity propagation
as described next.
The enriched gene sets were extracted from DEPICT
resource file containing the gene-gene set matrix of z-scores
for 19,987 genes. Next, pairwise Pearson correlation coef-
ficients were computed between all enriched gene sets, and
similar gene sets were clustered into biological themes
using affinity propagation clustering (using R package
apcluster 1.4.4) [14]. Affinity propagation finds exemplar
gene sets within the input gene sets that are representative
for each of the clusters, and names the clusters after their
exemplar gene set. As stated by the authors of DEPICT, the
reconstituted gene sets should be interpreted in light of the
genes that are mapped to them, since their identifiers are
simply carried over from the predefined gene sets used in
the development of DEPICT [13]. For the biological
themes, we addressed this issue by renaming the biological
theme, if necessary, after examining the main genes within
each biological theme (determined by the absolute weighted
mean z-score for each gene in the biological theme, using
the multiplicative inverse of the nominal p of each gene set
as a weight for each z-score).
Circulating endothelial cells during chemotherapy
as indicator of endothelial activation
As a measure of cancer treatment-induced endothelial
activation, the number of circulating endothelial cells
(CECs) were measured in 60 patients with metastatic TC
before and during three consecutive cycles of chemotherapy
with bleomycin, etoposide, and cisplatin (BEP) using
the CellSearch CEC Kit (Menarini Silicon Biosystems,
Huntingdon Valley, PA, USA) according to the supplier’s
protocol [15]. In short, blood was collected in Cell Save
Preservative tubes, and CECs were immunomagnetically
enriched targeting CD146 followed by staining of the
enriched cell population for CD45, CD105, and DAPI.
The CD146 enriched cells were classified as CECs when
CD105+/CD45−DAPI+ cells.
Results
Of the 379 genotyped patients, genotypes of 375 TC
patients and 237,087 SNPs passed quality analysis (Fig. 1).
All 375 TC patients had been treated with platinum-based
chemotherapy between 1977 and 2011 (Table 1). Most
chemotherapy regimens also contained bleomycin (n= 356,
95%). During a median follow-up of 11 years (range 3–37),
CVD had occurred in 53 cases (14%). These cases were
median 4 years older at start of chemotherapy than patients
who had no CVD (p= 0.009). At follow-up, cases met the
criteria for metabolic syndrome more often (67% versus
37%) and used more antihypertensive and lipid lowering
drugs than controls (p < 0.001 for all).
In total, 179 SNPs were associated at p ≤ 0.001 with the
occurrence of any CVD during or after chemotherapy
(Table S1). Clumping based on linkage disequilibrium
resulted in 141 independent loci containing a total of 324
SNPs. These 141 loci and corresponding SNPs were
annotated by finding nearest gene(s), cis or trans eQTLs, or
DEPICT gene prioritization (Table 2). Since DEPICT only
includes autosomal loci that do not overlap with the major
histocompatibility complex region, gene prioritization
resulted in 187 genes mapped to 129 loci.
Excluded at quality control:
Quality 
control
Cohort (n = 379)
(a) TC between 1977 and 2011, Royal 
Marsden Hospital stage II, III or IV
(b) treated with platinum-based chemotherapy
(c) age ≤55 years at diagnosis
(d) ≥3 years relapse-free follow-up*
(e) no prior chemotherapy or malignancy
(f) no cardiovascular disease prior to TC
Genotyped samples: n = 379
SNPs in array: m = 298,563
Samples after quality control: n = 375
SNPs after quality control: m = 237,087
Sample call rate <95% (n = 3)
Sex inconsistency (n = 1)
Minor allele frequency <5% (m = 50,708)
HW equilibrium p <0.0001 (m = 127)
SNP call rate <95% (m = 10,641)
Genotyping
Fig. 1 Patient selection and quality control. * ≥3 years relapse-free
follow-up after start of first-line chemotherapy, or after second-line
chemotherapy if given for early relapse within 3 years after TC
diagnosis. HW equilibrium: Hardy–Weinberg equilibrium.
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Table 1 Baseline patient and treatment characteristics and clinical follow-up data (n= 375).








Age at start chemotherapy (years) 31 (17–55) – 27 (16–55) – 0.009
Age at follow-up (years) 51 (24–72) – 41 (21–69) – <0.001
Follow-up duration (years) 12 (4–37) – 11 (3–37) – 0.03
Royal Marsden Hospital stage – 3 (1%) 0.46
Stage II 25 (47%) 179 (56%)
Stage III 6 (11%) 31 (10%)
Stage IV 22 (42%) 109 (34%)
IGCCCG classification 2 (4%) 3 (1%) 0.95
Good 33 (62%) 197 (61%)
Intermediate 14 (26%) 90 (28%)
Poor 4 (8%) 32 (10%)
Chemotherapy regime – – –
BEP followed by EP 18 (33%) 129 (40%)
BEP 17 (32%) 114 (35%)
PVB followed by PV maintenance 3 (6%) 16 (5%)
2 PVB followed by 2 BEP 1 (2%) 16 (5%)
PVB 4 (8%) 11 (3%)
EP 5 (9%) 8 (2%)
CEB 0 10 (3%)
Other platinum-based chemotherapy 5 (9%) 18 (6%)
Any radiotherapy 4 (8%) – 4 (1%) – –
Abdominal 2 (4%) 2 (0.6%)
Cranial 0 2 (0.6%)
Thoracic 1 (2%) 0
Contralateral testicle 1 (2%) 0
No radiotherapy 49 (93%) 318 (99%)
Cardiovascular events – – –
Any event 53 (100%) 0
Cardiomyopathya 6 (11%) –
Cerebrovasculara 8 (15%) –
Coronarya 19 (36%) –
Thromboembolica 19 (36%) –
Otherb 5 (9%) –
None 0 322 (100%)
Blood pressure at follow-up (mmHg) 3 (6%) 26 (8%)
Systolic 139 (110–190) 135 (105–190) 0.07
Diastolic 85 (60–112) 80 (50–124) 0.07
BMI at follow-up (kg/m²) 26.4 (19.4–40.6) 5 (9%) 25.5 (19.3–41.7) 58 (18%) 0.04
Waist-hip ratio at follow-up 1.0 (0.9–1.3) 8 (15%) 1.0 (0.8–1.3) 95 (30%) 0.60
Metabolic syndrome at follow-up 5 (9%) 75 (23%) <0.001
Yes 32 (60%) 92 (29%)
No 16 (30%) 155 (48%)
Antihypertensive drugs at follow-up – 4 (1%) <0.001
Yes 27 (51%) 52 (16%)
No 26 (49%) 266 (83%)
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Next, gene set enrichment analysis was performed in
DEPICT to gain insight in the biology underlying the asso-
ciations between SNPs and CVD, resulting in 33 gene sets
(p < 0.001, Table S2). These 33 gene sets were subsequently
clustered into ten distinct gene set clusters to highlight the
biological themes that are underlying the associations between
SNPs and CVD in chemotherapy-treated TC patients (Fig. 2
and Table S3). These biological themes included the RAC2/
RAC3 network, metabolism and adiposity, immune response,
and caspase cascade/apoptosis.
Since the most enriched gene sets were the RAC2 and
RAC3 subnetworks, clustered as the RAC2/RAC3 network,
we explored a biological readout of this finding. RAC2 and
RAC3 have been implicated in endothelial activation and
dysfunction [16, 17]. Therefore, as a measure of endothelial
activation, the number of CECs were measured over time in
60 patients with metastatic TC treated with chemotherapy.
A significant increase in CECs during three consecutive
cycles of platinum-based chemotherapy was observed
(Fig. 3).
Discussion
In this explorative GWAS using a contemporary strategy in
TC patients treated with platinum-based chemotherapy, we
determined which SNPs were associated with the occur-
rence of CVD after start of chemotherapy in these patients.
Table 1 (continued)








Lipid lowering drugs at follow-up – 3 (1%) <0.001
Yes 21 (40%) 27 (8%)
No 32 (60%) 292 (91%)
Antidiabetic drugs at follow-up – 3 (1%) 0.06
Yes 4 (8%) 7 (2%)
No 49 (93%) 312 (97%)
Testosterone suppletion at follow-up – 3 (1%) 0.75
Yes 2 (4%) 20 (6%)
No 51 (96%) 299 (93%)
Fasting glucose at follow-up (mmol/l) 5.6 (3.5–15.1) 3 (6%) 5.4 (1.3–9.4) 104 (32%) 0.05
Total cholesterol at follow-up (mmol/l) 4.6 (3.1–7.6) – 5.2 (2.8–9.7) 5 (2%) <0.001
HDL cholesterol at follow-up (mmol/l) 1.4 (0.8–4.9) 6 (11%) 1.2 (0.3–5.6) 56 (17%) 0.17
LDL cholesterol at follow-up (mmol/l) 2.9 (1.2–5.8) 6 (11%) 3.3 (0.4–6.5) 57 (17%) 0.03
Triglyceride at follow-up (mmol/l) 1.4 (0.5–4.7) – 1.4 (0.4–118) 4 (1%) 0.90
Total testosterone at follow-up (nmol/l) 13 (4.7–33) 6 (11%) 15 (0.7–160) 57 (18%) 0.01
eGFR at follow-up (ml/min/1.73 m²) 90 (18–127) – 92 (18–127) 4 (1%) 0.02
Albuminuria in 24 h urine at follow-up
(mg/24 h)
6 (0.9–1,152) 33 (62%) 8 (0–5,850) 158 (49%) –
Chronic kidney disease stage at follow-up – 4 (1%) 0.01
Stage 4 0 1 (0.3%)
Stage 3B 3 (6%) 1 (0.3%)
Stage 3A 2 (4%) 12 (4%)
Stage 2 26 (49%) 130 (40%)
Stage 1 22 (42%) 174 (54%)
Characteristics of TC patients with and without cardiovascular event were compared with Fisher’s exact test and Mann–Whitney U test after
removal of missing values, with two-sided p < 0.05 considered significant.
BEP bleomycin, etoposide, cisplatin, BMI body-mass index, CEB carboplatin, etoposide, bleomycin, eGFR estimated glomerular filtration rate,
EP etoposide, cisplatin, HDL high density lipoprotein, IGCCCG International Germ Cell Cancer Collaborative Group, LDL low-density
lipoprotein, PV cisplatin, vinblastine, PVB cisplatin, vinblastine, bleomycin.
aPatients with multiple cardiovascular events were counted in multiple categories.
bIntracerebral hemorrhage (n= 1), cardiac arrhythmia (n= 2), and cardiac valve regurgitation or stenosis (n= 2).
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Table 2 For the 141 identified candidate loci, related genes were found by proximity, cis or trans eQTLs, or by gene prioritization in DEPICT.
Locus SNPs p Genes
1 rs983098(*), rs1374038, rs10461655 0.00004 PARP8(d)
2 rs1352436(*) 0.00004 ENSG00000250546(d)
3 rs12692720(*), rs6432774, rs1528431,
rs6743187
0.00004 RND3(n,d), LINC01920(d)
4 rs199635(*), rs852937, rs543827,
rs473757, rs6918162
0.00004 LINC01626(n), LINC00472(d), OGFRL1(ce)
5 rs34814294(*) 0.00004 MMP28(n*,d), CCL5(d), HEATR9(d), RDM1
(d), TAF15(d), LYZL6(d)
6 rs3849324(*) 0.00008 MALL(n*,d), LINC00116(d), NPHP1(d)
7 rs6538046(*), rs10858436, rs4503615,
rs2406250, rs2406254
0.00008 MGAT4C(n*,d)







10 rs6687976(*), 0.00012 LINC01676(d)
11 rs2123269(*), rs2100346, rs6987013 0.00012 MRPS28(n*,d), TPD52(d,ce)
12 rs7744306(*), rs9347666, rs9456798,
rs10945861
0.00012 PACRG(n*,d), PARK2(n,d)
13 rs10950657(*), rs6968554, rs1476080 0.00012 AHR(n,d), LOC101927609(n#),
ENSG00000237773(d#), ENSG00000236318
(d#)
14 rs9459964(*) 0.00016 LOC105378150(n*#), ENSG00000232197(d#)
15 rs4466027(*), rs7673254, rs13121254 0.00016 LINC02261(n*), STIM2(d)
16 rs6988639(*), rs1433393, rs2656118 0.00016 SNTB1(d), HAS2(d)
17 rs12439991(*), rs7163517, rs11857756 0.00016 LOC105370777(n*), ENSG00000259450(d)
18 rs10932020(*), rs7591187 0.00016 CD28(d,ce)
19 rs6813846(*), rs9997501, rs892836 0.0002 STOX2(n*,d)
20 rs7748814(*), rs7742883, rs6914805,
rs6459467
0.0002 GMPR(d,ce), ATXN1(d,ce)
21 rs2331545(*) 0.0002 OVAAL(n*,d)
22 rs676740(*) 0.0002 AFDN(n*,d), ENSG00000235994(d)
23 rs1263635(*), rs943888 0.00024 TRAC(d)
24 rs755535(*), rs12108497, rs2130392,
rs4069938
0.00024 PRIMPOL(n,d,ce), CENPU(n,d,ce), ACSL1
(n), CASP3(d,ce)
25 rs11164896(*), rs2783499 0.00024 CCDC18(n,d,ce), DR1(d,ce), TMED5(d,ce),
MTF2(d), FNBP1L(d), CCDC18-AS1(d)
26 rs9324446(*), rs3887806, rs7837472 0.00024 FAM135B(d)
27 rs3934720(*) 0.00024 EIF2B5(d)
28 rs7702793(*) 0.00024 LOC105379160(n*#), GRAMD3(d)
29 rs10034996(*) 0.00024 ENSG00000251199(d)
30 rs1826613(*), rs1227842 0.00024 DLG2(n*,d)




0.00028 SPON1(n,d), PDE3B(d), RRAS2(d), COPB1
(d,ce)
32 rs1387092(*), rs1488745, rs6802020 0.00028 CNTN4(d)
33 rs17790008(*), rs6584652 0.00032 SORCS3(n*,d)
34 rs10828065(*), rs12355916 0.00032 PLXDC2(d)
35 rs596557(*) 0.00032 TMX3(d)
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Table 2 (continued)
Locus SNPs p Genes
36 rs17377955(*) 0.00032 DGKB(d)
37 rs11582429(*), rs2168951 0.00032 LINC01732(d)
38 rs9949956(*), rs8095771, rs12966370,
rs7236288, rs10871565
0.00032 LINC01029(n), GALR1(d)
39 rs6816525(*) 0.00032 IRF2(n*,d)
40 rs4896501(*), rs7753475 0.00032 CLVS2(d)
41 rs2554728(*) 0.00032 CSMD1(n*,d)
42 rs10503759(*), rs969456 0.00032 LOC101929294(n*#), ADAM7(d),
ENSG00000253643(d#), ADAMDEC1(ce)
43 rs4858795(*), rs6794875 0.00032 SHISA5(n*,d), PLXNB1(n,d), CCDC51(d),
FBXW12(d), PFKFB4(d,ce), TREX1(ce),
ATRIP(ce), NME6(ce), NCKIPSD(ce)
44 rs4662553(*) 0.00036 LRP1B(d)
45 rs17756443(*), rs16959991 0.00036 CDH13(n*,d)
46 rs5931289(*), rs5929883, rs5931353 0.00036 –
47 rs12920637(*), rs7198542 0.00036 CDH13(n*,d)
48 rs7745485(*), rs12524966, rs12198618 0.00036 LOC105374974(n#), HDGFL1(d)
49 rs6692(*), rs9555784 0.0004 ARHGEF7(n*,d,ce)
50 rs6467607(*) 0.0004 SLC13A4(d)
51 rs10902531(*) 0.0004 SFSWAP(d)
52 rs2215375(*) 0.0004 SPP2(d)
53 rs7101204(*) 0.0004 SVIL(n*,d)
54 rs1555145(*) 0.0004 BTBD3(d)




57 rs4432837(*), rs6864394 0.0004 RGS7BP(n*,d)
58 rs11736162(*), rs1439381, rs1439382,
rs7684647
0.00044 GUF1(d,ce), GNPDA2(ce)
59 rs9459963(*), rs9366130, rs4540249 0.00044 ENSG00000232197(d), DLL1(ce), FAM120B
(ce)
60 rs4676617(*) 0.00044 LOC102724104(n*#), CX3CR1(d,ce),
WDR48(ce)
61 rs11025878(*), rs4644637, rs7941875 0.00044 NELL1(n*,d)




64 rs1366906(*), rs6485532 0.00048 CD82(d)
65 rs3866223(*), rs11241999 0.00048 ADAMTS19(n*,d)
66 rs2275696(*), rs3892248 0.00048 NFASC(n*,d), DSTYK(ce)
67 rs12688573(*), rs5936239, rs2341921,
rs758439
0.00048 AFF2(n*)
68 rs2027469(*) 0.00048 CRP(d), DUSP23(ce)
69 rs11800877(*), rs4657327, rs1415439,
rs12076657
0.00048 PBX1(d)
70 rs2070584(*) 0.00052 TIMP1(n*)
71 rs28890299(*) 0.00052 LIPI(n*)
72 rs11643432(*), rs10514583 0.00052 CDH13(n*,d)
73 rs4237648(*), rs10742717, rs4237647,
rs1665150
0.00052 TSPAN18(n,d)
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Table 2 (continued)




75 rs9530423(*), rs1359500, rs9573531 0.00056 TBC1D4(n*,d)
76 rs7143719(*), 0.00056 TSHR(n*,d)
77 rs10822863(*), rs2894011, rs2894015,
rs4143863
0.00056 CTNNA3(n*,d)
78 rs7610664(*), rs7609933 0.00056 FGF12(n*,d)
79 rs6558831(*), rs12680491, rs11136689 0.00056 CSMD1(n*,d)
80 rs4751878(*), rs4752666, rs10887101,
rs6585804, rs11592039
0.00056 TACC2(n*,d)
81 rs12965155(*) 0.00056 MIR924HG(d)
82 rs760150(*) 0.00056 PCP4(n*,d), TMPRSS3(d)
83 rs239953(*) 0.00056 POR(n*,d,ce), RHBDD2(d,ce)
84 rs10182928(*) 0.00056 SATB2(d), SATB2-AS1(d)
85 rs617459(*), rs657426 0.0006 SETBP1(n*,d)
86 rs12165104(*), rs12954590 0.0006 TNFRSF11A(n*,d), ZCCHC2(d)
87 rs11688528(*) 0.00064 LOC100506474(n*#), TRIB2(d)
88 rs6966799(*) 0.00064 HDAC9(d)
89 rs6759648(*), rs7593846, rs9941639 0.00064 LINC01798(n*), MEIS1(d)
90 rs2973419(*) 0.00064 PRR16(d)




92 rs4795934(*), rs990510, rs12944367 0.00064 TMEM132E(d)
93 rs7831168(*), rs13269649, rs907991 0.00068 FAM135B(d)
94 rs9880546(*) 0.00068 LINC00578(n*), TBL1XR1(d)
95 rs1375547(*), rs9861237, rs9822731,
rs12498010, rs9880919
0.00068 CADM2(n*,d)
96 rs6557678(*), rs6988938, rs7824718,
rs7009973, rs7008867
0.00068 SLC25A37(d,ce), ENTPD4(ce), AC051642.5
(ce#)
97 rs16993897(*) 0.00068 VAV1(d), ADGRE1(ce)
98 rs16999330(*), rs4434196 0.00068 FSTL5(n*,d)
99 rs16880318(*), rs16880352 0.00072 KCNV1(d)
100 rs4947522(*), rs28633916, rs9642409 0.00072 COBL(d)
101 rs17078840(*) 0.00072 LINC00327(d)
102 rs40566(*) 0.00072 C5orf67(n*), MAP3K1(d)
103 rs4528743(*) 0.00072 SLC16A14(n*,d)
104 rs13249135(*) 0.00072 MIR2052HG(n*,d)
105 rs747925(*), rs11236683 0.00072 LOC105369395(n*#), THAP12(d)
106 rs10505371(*), rs17803964 0.00076 ENPP2(n*,d), TAF2(ce)
107 rs3911618(*) 0.00076 RGS7(n*,d)
108 rs7691972(*) 0.00076 ACSL1(n*,d), CASP3(ce)
109 rs6507498(*), rs9807753, rs8093542 0.00076 CABLES1(d)
110 rs7722584(*), rs11948927 0.00076 NLN(d)
111 rs3812278(*), rs10255837 0.00076 CNOT4(n*,d), NUP205(d)




114 rs4577099(*) 0.0008 LOC102724084(n*#), DYNLRB2(d)
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Subsequent gene set enrichment analysis resulted in ten
biological themes that highlight pathways that may be
involved in the occurrence of CVD in chemotherapy-treated
TC patients. These themes include the RAC2/RAC3 net-
work, metabolism and adiposity, immune response, and
caspase cascade/apoptosis.
Of special interest is the RAC2/RAC3 network that was
identified as a prominent biological theme. Several recent
reports link RAC2 and RAC3 to chemotherapy toxicity.
Rac2 deficiency protected Rac2−/− mice from bleomycin-
induced pulmonary fibrosis and resulted in lower mortality
compared to wildtype mice [18]. In a rat model, differential
Rac2 methylation was found in animals with acute lung
injury induced by lipopolysaccharide compared to controls
[19]. Although bleomycin-induced pneumonitis was not
the endpoint of the current GWAS, it is a well-known
side-effect of bleomycin in TC patients that originates
from endothelial activation and is linked to endothelial
Table 2 (continued)
Locus SNPs p Genes
115 rs8030490(*) 0.0008 AKAP13(n*,d,ce)
116 rs11610234(*), rs4334084 0.0008 TMEM132B(n*,d)
117 rs4762060(*) 0.0008 KRT80(n*,d), C12orf80(d)
118 rs6673313(*) 0.0008 LOC105378764(n*#), NFIA(d)
119 rs2506145(*) 0.00084 NRP1(n*,d)
120 rs898918(*), rs12100703 0.00084 LINC01550(d)
121 rs4607409(*), rs300121, rs777573,
rs9356411, rs9348092
0.00084 LINC00473(n,d), LOC105378117(n#), T(d),
MPC1(ce)
122 rs2147866(*), rs6891675 0.00084 CCDC192(n*), LINC01184(d)
123 rs8178838(*) 0.00088 APOH(n*,d), CEP112(d)
124 rs13406850(*), rs10172452, rs1628975 0.00088 LRP1B(d)
125 rs745247(*), rs7739748 0.00092 CD83(d)
126 rs6934819(*) 0.00092 ENPP3(d)
127 rs7916162(*) 0.00092 TACC2(n*,d), PLEKHA1(ce)
128 rs10764344(*), rs11013053 0.00092 PIP4K2A(n*,d), PIP5K2A(ce)
129 rs3003177(*) 0.00092 ENSG00000223786(d#)
130 rs949719(*), rs1516651 0.00092 ATP10B(n*,d)
131 rs938025(*) 0.00096 LINC00616(d), SLC7A11-AS1(d)
132 rs11640395(*) 0.00096 ZFHX3(n*,d)
133 rs2201369(*), rs10481102, rs13439041 0.00096 BAALC(n*,d), BAALC-AS2(d)
134 rs4521178(*) 0.00096 CPB1(n*,d), CPA3(d,ce)
135 rs1400438(*), rs1516893 0.00096 LINC01505(d)
136 rs9864293(*) 0.00096 IL1RAP(d)
137 rs2236570(*), rs613089 0.00096 BCL9(n*,d,ce), ACP6(d)
138 rs10868152(*), rs7022329 0.00096 SLC28A3(n*,d)











141 rs12750904(*) 0.001 ABCD3(n*,d,ce), F3(d)
Loci are ranked by p, which is the empirical p for association of the index SNP with cardiovascular events. Reference SNP cluster IDs are reported
for the index SNP (marked with an asterisk) and non-index clumped SNPs in the locus. For all SNPs in the locus, relevant genes were identified by
proximity to the index or non-index SNPs (annotated with n in parenthesis, with an asterisk denoting genes in proximity to the index SNP).
Additional relevant genes are reported based on cis and trans eQTLs (annotated with ce and te, respectively), and based on gene prioritization in
DEPICT (annotated with d). Genes are reported by HGNC gene symbol if possible, or alternatively by Ensemble identifiers if no HGNC gene
symbol exists.
DEPICT data-driven expression-prioritized integration for complex traits, eQTL expression quantitative trait loci, HGNC human genome
organisation gene nomenclature committee, SNP single nucleotide polymorphism.
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dysfunction [20, 21]. Indeed, RAC2 has been implicated in
endothelial activation and neovascularization, as well as
leukocyte adhesion to the endothelial cell [16, 22]. In an
atherosclerosis model, Rac2 prevented plaque calcification
by suppressing macrophage IL-1β expression. Furthermore,
decreased RAC2 expression and increased IL-1β expression
were found in calcified coronary arteries from patients [23].
Rac1/2 pathways were involved in vascular injury in dia-
betic mice [24]. RAC3 has been suggested to inhibit
senescence, and RAC3 expression is involved in the
inflammatory response after TNF stimulation [25, 26].
Moreover, Rac3 modifies the induction of endothelial dys-
function by oxidized low-density lipoprotein in human
umbilical vein endothelial cells [17]. Thus, the RAC2/
RAC3 network may play a role in atherosclerosis and
senescence—pathophysiologic processes that have been
implicated in the progress of CVD in TC patients—as well
as bleomycin-induced pneumonitis. Interestingly, SNPs in
RAC2 have also been found associated to cardiotoxicity due
to anthracycline chemotherapy, suggesting that the RAC2/
RAC3 network is a common denominator in cardiovascular
toxicity of multiple chemotherapeutic agents [27]. The
occurrence of pathophysiological processes in which the
RAC2/RAC3 network is involved, is illustrated in a cohort
of 60 TC patients with the observation that the number of
CECs increases during consecutive cycles of platinum-
based chemotherapy as sign of endothelial activation.
The biological themes of metabolism and adiposity,
immune response, and caspase cascade/apoptosis are of
particular interest, because these processes have been linked
in literature to cardiovascular toxicity of platinum che-
motherapy. The role of metabolism, adiposity, and endo-
crine dysfunction in the development of CVD has been well
described in TC patients [28–30]. Besides this, the role of
inflammation and immune response has been established in
murine and cell models of platinum-induced nephrotoxicity,
Reconstituted gene set (source) [p x 10-4]
NAT9 subnetwork (ENSG) [1.10]
NOD1 subnetwork (ENSG) [8.08]
RAC3 subnetwork (ENSG) [0.12]
RAC2 subnetwork (ENSG) [0.13]
Protein kinase binding (GO) [9.31]
Kinase binding (GO) [9.54]
Non−small cell lung cancer (KEGG) [0.32]
RAF1 subnetwork (ENSG) [0.52]
Acute myeloid leukemia (KEGG) [1.40]
CTNNB1 subnetwork (ENSG) [1.78]
CEBPB subnetwork (ENSG) [2.23]
Signalling by NGF (Reactome) [2.98]
Downstream signal transduction (Reactome) [4.06]
TGOLN2 subnetwork (ENSG) [4.96]
MAP2K1 subnetwork (ENSG) [7.12]
NGF receptor signaling pathway (GO) [8.19]
DAG and IP3 signaling (Reactome) [4.18]
PLCG1 events in ERBB2 signaling (Reactome) [5.68]
Protein serine/threonine/tyrosine kinase activity (GO) [1.63]
MAP kinase kinase activity (GO) [2.83]
Phosphoric ester hydrolase activity (GO) [4.19]
Phosphoprotein phosphatase activity (GO) [8.15]
Phosphatase activity (GO) [8.64]
Abnormal osteoclast differentiation (MP) [1.90]
Increased percent body fat (MP) [3.31]
Prolonged estrous cycle (MP) [3.54]
Reduced female fertility (MP) [8.98]
Downstream TCR signaling (Reactome) [3.81]
TCR signaling (Reactome) [5.33]
Enlarged lymph nodes (MP) [8.06]




































































































































































































































































































































Pearson r 0.00 0.25 0.50 0.75 1.00
NGF signalling via TRKA (Reactome) [7.97]
EGFR interacts with PLCG1 (Reactome) [5.22]
Fig. 2 The 33 gene sets that were enriched according to DEPICT
were clustered into ten biological themes. The reconstituted gene
sets were named after the predefined gene sets used in the development
of DEPICT, and source databases are reported in brackets. The
nominal enrichment p for each reconstituted gene set as reported by
DEPICT is reported in brackets, with emphasis added for gene sets
with p < 1 × 10−4. Clustering into biological themes was performed
using affinity propagation clustering after calculating pairwise Pearson
correlation between all enriched gene sets, as depicted in the bubble
chart. CEBPB: CCAAT/enhancer binding protein beta, CTNNB1:
catenin beta 1, DAG: diacylglycerol, EGFR: epidermal growth factor
receptor, ENSG: Ensembl gene, ERBB2: erb-b2 receptor tyrosine
kinase 2, GO: gene ontology, IP3: inositol triphosphate, KEGG:
Kyoto Encyclopedia of Genes and Genomes, MAP: mitogen-activated
protein kinase, MAP2K1: MAP kinase kinase 1, MP: mammalian
phenotype ontology, NAT9: N-acetyltransferase 9, NGF: nerve growth
factor, NOD1: nucleotide binding oligomerization domain containing
1, PLCG1: phospholipase C, gamma 1, RAC2: ras-related C3 botuli-
num toxin substrate 2, RAC3: ras-related C3 botulinum toxin substrate
3, RAF1: Raf-1 proto-oncogene, serine/threonine kinase, TCR:
T cell receptor; TGOLN2: trans-golgi network protein 2, TRKA:
tropomyosin receptor kinase A.
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evidenced by upregulation of TNF-α and a direct mediating
role of T lymphocytes [31–35]. The biological theme
involving caspase activation and apoptosis is illustrated by
murine and in vitro experiments indicating the role of cas-
pase 1 and caspase 3 in platinum-induced nephrotoxicity, as
well as endothelial cell apoptosis in response to cisplatin
administration [20, 36, 37].
The low absolute incidence of TC and of CVD in
chemotherapy-treated TC patients poses a challenge to
perform meaningful GWAS on toxicity. Therefore, the
current exploratory GWAS aimed to find relevant gene sets
and possible biological themes rather than specific SNPs.
To this end, the study was designed to minimize type II
statistical errors whilst accepting a higher probability of
type I statistical errors: in the trade-off between false posi-
tives and negatives, we avoided false negatives. Conse-
quently, the current study should be regarded as hypothesis-
generating and the highlighted biological themes should be
regarded as providing a promising base for future studies on
genetic susceptibility and relevant biomarkers in CVD in
TC patients. In this regard, results from the ongoing trials
on genetic variation in TC survivors in relation to renal and
cardiovascular toxicity (NCT02303015), as well as oto-
toxicity and neurotoxicity (NCT02890030, NCT02677727)
are awaited.
The need to study SNPs associated with CVD in the
specific population of TC patients derives from the notion
that involved SNPs might differ from the currently known
SNPs associated with increased risk of CVD in the general
population. Indeed, only two of the 179 SNPs associated
with CVD in the current GWAS were recorded to be
associated with any cardiovascular phenotype in the
NHGRI-EBI Catalog of published GWAS (catalog release
11 December 2017): rs2130392 and rs6773957 were asso-
ciated with Kawasaki syndrome and adiponectin levels,
respectively [38]. Nevertheless, future research should not
only aim at exploring and validating results from genetic
studies in TC cohorts, such as the biological themes high-
lighted in the current analysis, but also investigate the value
of genetic risk scores derived from CVD GWAS in the
general population.
The major strengths of this GWAS are the well-defined
cohort, the completeness of follow-up, and the clinical
relevance of addressing susceptibility to CVD in TC
patients. Two additional remarks should be made on
the study design. First, a broad definition of CVD (both
venous and arterial) was used to define cases, because a
stricter definition of only arterial events would unwarran-
tably compromise statistical power. Second, as we inclu-
ded patients treated from 1977 to 2011, follow-up duration
varied widely, although selection bias in this regard may
be considered unlikely given only a 1 year longer median
follow-up duration for the cases compared to the control
group, and equal ranges of follow-up duration for both
groups.
Conclusions
In this exploratory GWAS, ten biological themes were
linked with the occurrence of CVD in platinum-treated TC
patients. These biological themes include metabolism and
adipositas, immune response, apoptosis, and most promi-
nently the RAC2/RAC3 network. This network has been
implicated in bleomycin-induced lung injury, vascular
oxidative stress, premature senescence, and endothelial
activation. The biology of the RAC network was illustrated
by observed CEC induction as sign of endothelial activation
during consecutive courses of cisplatin-based chemotherapy
in a TC cohort. Insight in the genetic variants determining
susceptibility to CVD in TC patients can aid in the devel-
opment of intervention strategies to prevent long-term
sequelae of chemotherapy in often young cancer survivors.
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Fig. 3 The number of CECs rises during three cycles of BEP
chemotherapy, based on measurements in 665 blood samples in 60
TC patients. Depicted are (a) the mean number of CECs per patient
during each cycle, and (b) all CEC measurements with a LOESS
curve. During the three consecutive cycles of chemotherapy the mean
number of CECs per patient were median 32/ml (interquartile range,
IQR 24–50), 58/ml (IQR 35–91), and 82/ml (20–117), respectively.
Compared to the first cycle, the mean number of CECs was increased
in the second and third cycle of chemotherapy (Wilcoxon signed rank
test p < 0.001). BEP: bleomycin, etoposide, cisplatin, CEC: circulating
endothelial cell.
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